Cover Image
市場調查報告書

睪固酮替代療法 (TRT) 的全球市場

Testosterone Replacement Therapy (TRT)

出版商 Global Industry Analysts, Inc. 商品編碼 236874
出版日期 內容資訊 英文 166 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
睪固酮替代療法 (TRT) 的全球市場 Testosterone Replacement Therapy (TRT)
出版日期: 2015年01月01日 內容資訊: 英文 166 Pages
簡介

本報告提供全球睪固酮替代療法市場相關調查、各產品區隔趨勢、各地區趨勢、2013年∼2020年的預測、市場參與企業簡介等彙整資料。

第1章 簡介、調查方法、產品定義

第2章 摘要整理

  • 產業概要
    • 睪固酮缺乏症的高發病率可能成長
    • 最近核準的/開發平台的睪固酮替代療法產品
    • 美國壟斷全球睪固酮替代療法市場
    • 美國以外的市場也顯示很大的成長
    • 局部治療壟斷美國市場
    • 市場上可取得的主要產品
    • 心血管風險睪固酮替代療法市場壞影響
  • 促進成長要素與市場趨勢
    • 高齡化
    • 未診斷患者
    • 意識提升
    • 對共生病症有好影響的相關新資料
    • 行銷的動向和患者的介紹促進成長
    • 容易使用的製劑
    • 未開發的發展中國家市場
    • 為了治療其他症狀的睪固酮 其他
  • 競爭
    • 十分整合的市場
    • 大型跨國企業的進入
    • 非專利的崛起
    • 專利的失效和美國的領導品牌的市場壟斷
  • 市場上主要藥物概要
  • 睪固酮缺乏症
  • 產品上市/認證
  • 近幾年的產業活動
  • 全球參與企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
  • 亞太地區
  • 南美
    • 巴西

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6770

This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as -

AbbVie, Inc.
Acrux Limited
Actavis, Inc.
Antares Pharma, Inc.
Auxilium Pharmaceuticals, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Topicals
    • Patches
    • Others

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • High Incidence of Testosterone Deficiency Offers Growth Potential
    • Table 1: World Hypogonadism Prevalence by Age Group: Percentage of the Disorder in 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, and >80 Age Groups (includes corresponding Graph/Chart)
  • Recently Approved/ Pipeline Testosterone Replacement Therapy Products
  • US Dominates the Global TRT Market
  • Markets, Other than the US, to Witness Tremendous Growth
  • Topicals Dominate the US Market, Conventional Drugs Rule Elsewhere
  • Leading TRT Products Available in the Market
  • Cardiovascular Risks Taint the TRT Market

2. GROWTH DRIVERS AND MARKET TRENDS

  • Aging Global Population Drives Adoption
    • Table 2: Percentage of Total Population above 65 Years of Age in Select Countries for 2000 and 2025(F) (includes corresponding Graph/Chart)
    • Table 3: Global Male Population Distribution (15-64 Yrs) by Geographic Region/Country: 2010 (includes corresponding Graph/Chart)
    • Table 4: Global Male Population Distribution (65+Yrs) by Geographic Region/Country: 2010 (includes corresponding Graph/Chart)
    • Table 5: Top 20 Countries with Male Population Aged 15 - 64: 2010 (in Millions) (includes corresponding Graph/Chart)
    • Table 6: Top 20 Countries with Male Population Aged 65 & Above: 2010 (in Millions) (includes corresponding Graph/Chart)
  • Undiagnosed Patients - A Strong Indicator of Growth Potential
  • Rising Awareness - A Critical Factor for Growth
  • Emerging Data on Positive Impact on Co-morbidities to Support Growth
  • Marketing Campaigns and Patient Referrals to Fuel Growth
  • Easy-to-use Formulations - A Major Boost to TRT Market
  • Untapped Developing Markets - The Future Growth Engine for TRT
  • Testosterone as Treatment for Other Conditions - A Growing Area of Focus
  • FDA Rejects Citizen "Black Box" Petition
  • Aggressive DTC Advertising Eases in 2014

3. COMPETITION

  • TRT- A Highly Consolidated Market
    • Table 7: World Testosterone Replacement Therapy Products Market by Leading Player (2012 & 2013): Percentage Market Share Breakdown of Value Sales for AndroGel, Testim, Androderm, Axiron, Testopel, and Fortesta (includes corresponding Graph/Chart)
  • Entry of Large Multinational Players
  • Generic Incursion - A Major Threat
  • Expiration of Patents and Market Exclusivity of Leading TRT Brands in the US

4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET

  • AndroGel (AbbVie)
  • Axiron (Eli Lilly)
  • Axiron - A Comparison with Other Products
    • Axiron's Patent Profile
  • Testim (Auxilium)
    • Table 8: Global Market of Testim by Geographic Region (2012 & 2013): Breakdown of Annual Value Sales Markets in US$ Million for US and Rest of World (includes corresponding Graph/Chart)
  • Testim Scores High on Efficacy over AndroGel
  • Small Packaging Works for Testim
  • Androderm (Actavis)
  • Fortesta (Endo Pharmaceuticals)
  • Tostran (Prostrakan Group)
  • Threat from New Products
  • Pipeline Analysis
  • Oral Drugs Dominate Drug Development Pipeline
  • An Overview of Select Drugs in Pipeline
    • Natesto(tm) TRT - A Comparative Review
    • VIBEX QS T - A New Hope to Injectables Users
    • Androxal
    • Rextoro (formerly CLR-610)

5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW

  • Testosterone - An Introduction
  • Testosterone Deficiency
  • Primary Hypogonadism
  • Secondary Hypogonadism
  • Symptoms
  • General Symptoms
  • Clinical Symptoms
    • Table 9: Major Symptoms in Hypogonadal Patients: Percentage of Hypogonadal Patients Affected with Moderate to Severe Symptoms of Low Energy Levels, Irritability, Sparse Beard, Diminished Libido, and Sleepiness After Lunch (includes corresponding Graph/Chart)
    • Causes
  • Co-Morbid Conditions
    • Table 10: Hypogonadism Prevalence in Some Common Medical Conditions (includes corresponding Graph/Chart)
  • Diabetes and Hypogonadism
  • Diagnosis
  • Testosterone Replacement
  • Testosterone Replacement Therapy - Evolution
  • Topicals
  • Patches
  • Others
    • Injections
    • Orals
    • Pellets
  • A Comparison of Key Benefits and Drawbacks of Existing Testosterone Preparations
  • Major Potential Benefits of TRT
  • Major Potential Risks of TRT
  • Precautions
  • Treatment Alternatives

6. PRODUCT LAUNCHES/APPROVALS

  • FDA Denies Rextoro Oral Testosterone by Clarus Therapeutics
  • FDA Approves sNDA for STENDRA
  • Endo International Launches Generic Version of its Fortesta
  • MonoSol Rx Launches Clinical Trial of MSRX-110
  • Perrigo Receives AB Therapeutic Equivalent Rating from FDA for Testosterone Gel
  • FDA Confirms Endpoints for ZA-304 and ZA-305 Studies
  • Auxilium and Prasco Launch Testim(r) Generic
  • FDA Approves NDA for Vogelxo
  • USFDA Approves Natesto Testosterone Nasal Gel
  • BioThermo Labs Introduces T9 Testosterone Supplement
  • iSatori Launches Fenu Test
  • HRTI Obtains FDA Clearance for Commencing Testagen(r) TDS Clinical Trials
  • Eli Lily Launches Axiron(r) in Canada
  • FDA Approves Generic Depo-Testosterone Injection of Sun Pharmaceutical
  • Perrigo Obtains FDA Approval for AndroGel(r) 1%
  • TestoMeds Launches Androfeme, Andromforte and Profeme Testosterone Replacement Creams
  • BioSante's Bio-T-Gel(tm) Receives FDA Clearance

7. RECENT INDUSTRY ACTIVITY

  • TesoRx Awards Aspen Global with Select International License of TSX-002
  • Viramal Acquires TestoCream License from Aptys
  • Vivus Provides Auxilium North American Marketing Rights for STENDRA
  • CoreRx and TesoRx Pharma Form Production Joint Venture for TSX-002
  • Eli Lilly Files Lawsuit against Perrigo for Infringing Axiron Patents
  • Perrigo Files for Generic Axiron Approval with FDA
  • Auxilium Wins Patent Challenges for Testim
  • Auxilium Pharmaceuticals Takes Over Actient Holdings
  • Ferring Submits Patent Application for New Testosterone Formulations in Australia
  • Perrigo Submits ANDA for Testosterone 1.62% with the US FDA
  • Watson Pharmaceuticals Rebrands to Actavis
  • US FDA Accepts to Review Complete Response Submission for NDA of Endo Pharmaceuticals' Aveed
  • Lipocine Announces Positive Phase I Clinical Trial for LPCN 1111 Candidate
  • Auxilium Pharmaceuticals and GlaxoSmithKline Enter into Co-Promotion Deal for Testim Gel
  • Lipocine Receives Approval for Phase III Study of LPCN 1021 from US FDA
  • Clarus Therapeutics Announces Positive Phase III Clinical Trial Data for CLR-610 Oral TRT
  • Watson Laboratories Submits ANDA for Testosterone 1% Gel to US FDA

8. FOCUS ON SELECT PLAYERS

  • AbbVie, Inc. (US)
  • Acrux Limited (Australia)
  • Actavis, Inc. (US)
  • Antares Pharma, Inc. (US)
  • Auxilium Pharmaceuticals, Inc. (US)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Columbia Laboratories, Inc. (US)
  • Eli Lilly and Company (US)
  • Endo Pharmaceuticals Inc. (US)
  • ProStrakan Group PLC. (UK)
  • Trimel Pharmaceutical Corporation (Canada)

9. GLOBAL MARKET PERSPECTIVE

    • Table 11: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy (TRT) by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 12: World Historic Review for Testosterone Replacement Therapy (TRT) by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 13: World 15-Year Perspective for Testosterone Replacement Therapy (TRT) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 14: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy (TRT) by Product Segment - Topicals, Patches, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review for Testosterone Replacement Therapy (TRT) by Product Segment - Topicals, Patches, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 16: World 15-Year Perspective for Testosterone Replacement Therapy (TRT) by Product Segment - Percentage Breakdown of Dollar Sales for Topicals, Patches, and Other Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Hypogonadism - High Prevalence, Low Treatment, Offers Increasing Potential
    • Topical Gels - The Largest Selling Segment
    • Table 17: The US TRT Market by Leading Brand (2012 & 2013): Percentage Market Share Breakdown of Revenues for Androderm, Androgel, Axiron, Fortesta, Injections, Testim, and Others (includes corresponding Graph/Chart)
    • Table 18: Total TRT Annual Transdermal Prescriptions in the US: Number of Total Prescriptions (Nov 2012 - June 2014) (includes corresponding Graph/Chart)
    • A Comparison of Commonly Prescribed Topical TRT Products in the US
    • "Low T" Trend Litigations
    • New Products Strive to Address Transference Issues
    • High-Concentration Products Gain Market Share in the Topicals Market
    • Debate Continues Over the Need for TRT
    • Big Pharma Spends Millions to Push TRT Sales
    • Table 19: The US Ad Spending on Testosterone Products: 2010- 2014 (1st Half) (includes corresponding Graph/Chart)
    • Increasing Ad Spending Draws Flak
    • Product Landscape
      • AndroGel Retains Leadership in Total Prescriptions
    • Table 20: The US Testosterone Gel and Patch Market by Leading Player (Mid 2013 & Mid 2014): Percentage Market Share Breakdown of Total Prescriptions for AndroGel (1% & 1.62%), Androderm, Axiron, Fortesta, and Testim (includes corresponding Graph/Chart)
      • AbbVie Fights on for AndroGel's Market Sustenance
      • Axiron Regains Growth Momentum
    • Table 21: Axiron Quarterly Sales in the US: 2011 through 2014 (includes corresponding Graph/Chart)
      • Co-Pay Scheme Helps Axiron Attract Users
      • Testim Prescriptions Shoot up, Revenues Head South
      • Impending Patent Expiries
      • Patent Expiries of Leading TRT Brands in the US
      • Generics in the Pipeline
      • List of Testosterone Generics in the Pipeline for US Market
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 22: The US Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Product Segment - Topicals, Patches, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 23: The US Historic Review for Testosterone Replacement Therapy by Product Segment - Topicals, Patches, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 24: The US 15-Year Perspective for Testosterone Replacement Therapy by Product Segment - Percentage Breakdown of Dollar Sales for Topicals, Patches, and Other Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Available TRT Therapies in Canada
    • Competitive Scenario
    • Product Approval/Launch
    • Trimel Pharmaceutical Corp. - A Key Canadian Player
  • B. Market Analytics
    • Table 25: Canadian Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 26: Canadian Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Gels to Drive European TRT Market
    • Lower Normal Serum Testosterone Concentration in Select European Nations
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European Historic Review for Testosterone Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 29: European 15-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3a. FRANCE

  • Market Analysis
    • Table 30: French Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 31: French Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3b. GERMANY

  • A. Market Analysis
    • Bayer Healthcare Pharmaceuticals - A Key Player
  • B. Market Analytics
    • Table 32: German Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: German Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3c. ITALY

  • Market Analysis
    • Table 34: Italian Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: Italian Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Market Overview
    • Table 36: The UK TRT Market by Product Type (2012): Percentage Breakdown of Value Sales for Topical Gels, Injectables, Patches, and Oral Products (includes corresponding Graph/Chart)
    • Product Launch/Approval
    • Strategic Corporate Development
    • Select Key Player
  • B. Market Analytics
    • Table 37: The UK Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 38: The UK Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3e. SPAIN

  • Market Analysis
    • Table 39: Spanish Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 40: Spanish Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3f. REST OF EUROPE

  • Market Analysis
    • Table 41: Rest of European Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 42: Rest of European Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Increasing Use of Testosterone in Australia
    • Strategic Corporate Development
    • Select Key Player
  • B. Market Analytics
    • Table 43: Asia-Pacific Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 44: Asia-Pacific Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. LATIN AMERICA

  • Market Analysis
    • Table 45: Latin American Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 46: Latin American Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 47: Rest of World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 48: Rest of World Historic Review for Testosterone Replacement Therapy Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top